Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Obstetrics and gynaecology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Venous thromboembolism risk and anticoagulation

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Suspected pulmonary embolism needs immediate assessment

Sudden breathlessness, pleuritic chest pain, haemoptysis, syncope or collapse during pregnancy or postpartum may represent pulmonary embolism.

Action: Arrange emergency hospital assessment, support airway and circulation, obtain objective testing and start therapeutic LMWH while investigation proceeds unless strongly contraindicated; haemodynamic instability requires immediate senior multidisciplinary consideration of reperfusion and critical care.

Overview

Repeatedly assess pregnancy-associated thrombosis risk, investigate suspected venous thromboembolism without delay, and prescribe anticoagulation with safe delivery and neuraxial timing.

Pregnancy promotes thrombosis through hypercoagulability, venous stasis and vascular injury around birth. The postpartum period is particularly hazardous, but DVT and PE can occur in any trimester. Risk assessment must be repeated when the clinical situation changes: admission with hyperemesis, infection, immobilisation, surgery, pre-eclampsia or postpartum haemorrhage may alter a previously low-risk plan. Explain the reason for prophylaxis and how to administer it; an unsigned risk score without a prescription and practical teaching prevents nothing.

Use the maternity service's RCOG-based assessment rather than inventing an additive score. Previous thrombosis, strong thrombophilia, significant medical disease and combinations of common factors carry different weights. Four current listed risk factors generally justify considering prophylaxis throughout pregnancy, three from 28 weeks and two for at least ten days after birth. Prior VTE and specific thrombophilias require their own pathways, and antenatal prophylaxis often leads to six weeks postpartum after reassessment.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Safe neuraxial timing

A woman receiving therapeutic enoxaparin for a recent pregnancy-associated DVT arrives in labour. Her last treatment dose was eight hours ago and she requests an epidural. What is the most appropriate response?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status4 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • RCOG Green-top 37a: VTE prevention in pregnancy and puerperium
  • RCOG Green-top 37b: Acute thromboembolic disease in pregnancy
  • RCOG: Diagnosis and treatment of venous thrombosis in pregnancy
  • NHS: Deep vein thrombosis

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
A prior event needs careful characterisation: site, objective confirmation, provoking factors, recurrence, anticoagulant duration and thrombophilia history. An unprovoked or oestrogen-associated event differs from a single episode after major surgery with no additional risk factors. Arrange an early haematology–obstetric plan for recurrent VTE, antithrombin deficiency, thrombotic antiphospholipid syndrome or long-term anticoagulation. Do not reduce these situations to a routine 40 mg enoxaparin prescription.

Suspected acute thrombosis requires objective investigation. Start therapeutic LMWH while arranging testing unless bleeding or another strong contraindication changes the balance. For leg symptoms, compression duplex ultrasound is the initial test; extensive whole-leg swelling with buttock or back pain can indicate iliac thrombosis, which may need dedicated pelvic imaging. After a negative leg scan with high suspicion, the RCOG serial-ultrasound pathway repeats testing on days three and seven and specifies withholding anticoagulation during that interval, with senior review if symptoms or imaging limitations create additional concern.

For possible PE, assess haemodynamic stability and obtain ECG and chest radiography. When DVT signs coexist, a positive leg scan can establish VTE and avoid further chest imaging. Otherwise use CTPA or ventilation–perfusion imaging; an abnormal chest radiograph favours CTPA in RCOG guidance. Explain maternal and fetal radiation considerations without exaggerating them. Do not use an ordinary Wells score or a standalone D-dimer to exclude PE in pregnancy; any newer pregnancy-adapted algorithm must be used through an agreed specialist pathway.

LMWH does not cross the placenta and is the usual treatment for pregnancy-associated VTE. Calculate dose from booking or early-pregnancy weight using the chosen product and maternity treatment protocol, considering renal function, extremes of weight and recurrent thrombosis. Routine anti-Xa measurement is unnecessary for most standard cases but can be considered for defined high-risk circumstances. Unfractionated heparin may be useful when rapid reversibility, severe renal impairment or an unstable PE makes it preferable.

Prepare delivery planning before the last weeks of pregnancy. Record prophylactic versus therapeutic intensity, the last dose, planned birth timing, neuraxial restrictions and what to do when spontaneous labour or bleeding starts. Epidural haematoma risk depends on timing, renal clearance, dose and procedural factors. Minimum intervals are not an automatic declaration of safety after traumatic placement or significant renal impairment. The anaesthetist and prescriber must agree catheter removal and anticoagulation restart.

Continue treatment for an acute VTE for at least three months overall and at least six weeks after birth. LMWH and warfarin are established breastfeeding-compatible options; postpartum oral anticoagulant selection needs current drug-specific advice and is distinct from pregnancy prescribing. At follow-up assess bleeding, adherence, residual symptoms and future pregnancy planning. Persistent breathlessness after PE deserves evaluation rather than indefinite reassurance about normal postnatal recovery.

Key points

  • Document VTE risk at booking, during admission or new illness, and after birth; risk changes throughout pregnancy and the puerperium.
  • RCOG generally considers four current risk factors for antenatal LMWH, three for LMWH from 28 weeks and two for at least ten days postpartum, with separate pathways for prior VTE and thrombophilia.
  • Most previous VTE histories warrant antenatal LMWH; the single major-surgery-provoked event without other risks is an important specialist-assessed exception.
  • Compression duplex ultrasound investigates suspected DVT; if negative but suspicion remains high, RCOG specifies repeat scans on days three and seven.
  • Investigate suspected PE with appropriate chest imaging; a normal oxygen saturation, normal ECG or prophylactic heparin does not rule it out.
  • Use weight-adjusted LMWH for confirmed VTE and continue through pregnancy for at least six weeks postpartum and at least three months in total.
  • For standard prophylactic LMWH allow at least twelve hours before neuraxial procedures; for therapeutic LMWH allow at least twenty-four hours, with anaesthetic review of modifiers.
  • If labour or vaginal bleeding starts, omit further LMWH and contact maternity services for reassessment and a supervised plan.

Aetiology

01

Pregnancy and birth

Pregnancy-related coagulation changes and venous compression combine with tissue injury at delivery, producing risk throughout gestation and particularly after birth.

02

Additional risk factors

Previous VTE, thrombophilia, obesity, immobility, infection and significant medical disease can compound pregnancy risk and alter the timing or intensity of prophylaxis.

Pathophysiology

  1. 1
    Venous stasis

    Reduced venous flow from hormonal effects, uterine compression and immobility facilitates clot formation, particularly in the deep pelvic and leg veins.

  2. 2
    Procoagulant balance

    Changes in clotting factors and natural anticoagulant activity favour haemostasis around delivery but also increase susceptibility to pathological thrombosis.

  3. 3
    Pulmonary embolisation

    A venous thrombus can travel to the pulmonary circulation, increasing right ventricular load and causing hypoxaemia, shock or sudden collapse.

Clinical features and red flags

Leg and pelvic thrombosis

New unilateral swelling or pain is concerning, and proximal pelvic disease may cause groin, buttock or back pain with whole-leg enlargement.

Pulmonary presentation

Abrupt breathlessness, pleuritic pain, haemoptysis or syncope can occur with minimal chest examination findings or initially normal oxygen saturation.

Changing prophylaxis need

Admission, infection, dehydration, immobility or new obstetric complications should trigger reassessment rather than reliance on the booking score.

Anticoagulant harm

Unexpected bruising, bleeding, a falling platelet count or neurological symptoms after neuraxial procedures require urgent treatment-safety review.

Red flags requiring action

  • Chest pain with acute breathlessness, syncope, hypoxia or haemoptysis requires urgent assessment for pulmonary embolism even if the patient is already receiving prophylaxis.
  • Unilateral whole-leg swelling, groin or buttock pain, or marked new asymmetry warrants urgent imaging for proximal or pelvic thrombosis.
  • Major bleeding, new neurological symptoms after neuraxial procedures or suspected heparin-induced thrombocytopenia requires immediate review of anticoagulation.

Investigations

  1. 01
    Compression duplex ultrasoundFirst step
    Why
    Demonstrate lower-limb venous thrombosis objectively when symptoms suggest DVT.
    Interpretation and limitations
    A negative scan with persistent high suspicion needs a planned serial-imaging pathway; consider iliac or pelvic imaging for proximal symptoms.
  2. 02
    ECG and chest radiograph
    Why
    Identify alternative diagnoses and help select PE imaging.
    Interpretation and limitations
    Neither test excludes pulmonary embolism; an abnormal radiograph often makes CTPA the more informative next investigation.
  3. 03
    CT pulmonary angiography or V/Q imaging
    Why
    Confirm or exclude PE when a chest study is required.
    Interpretation and limitations
    Choose with radiology using the clinical situation and radiograph; if imaging is nondiagnostic, arrange further testing rather than equating uncertainty with exclusion.
  4. 04
    Blood count, renal and liver function, coagulation screen
    Why
    Establish anticoagulation safety and identify factors affecting dose or bleeding risk.
    Interpretation and limitations
    Obtain baseline samples without delaying urgent heparin when appropriate; severe renal dysfunction may require a different drug or dose.
  5. 05
    Selected anti-Xa or thrombophilia testing

Differential diagnosis

01

Dependent pregnancy oedema

Bilateral gradual swelling without focal symptoms may be physiological, but unilateral or whole-leg changes need assessment rather than attribution to normal fluid retention.

02

Cellulitis or muscle injury

Local inflammation or injury can mimic DVT, and clinical appearance alone cannot reliably separate these diagnoses when thrombotic risk is significant.

03

Cardiac or respiratory disease

Pneumonia, pneumothorax and peripartum cardiomyopathy can resemble PE; investigation should address competing emergencies without prematurely closing the diagnostic pathway.

Management

01PreventionTranslate risk assessment into a usable planFirst stepAntenatal booking, hospital admission, new risk factors or birth changes thrombosis risk.+
  1. 1Complete the appropriate maternity assessment and identify prior VTE or thrombophilia that requires a separate specialist pathway.
  2. 2Prescribe the correct prophylactic dose and duration when indicated, checking weight, renal function, bleeding and neuraxial considerations.
  3. 3Teach injection technique, safe sharps handling and when to withhold a dose, and confirm the patient can obtain the full prescribed course.
02Acute suspicionAnticoagulate and investigate in parallelClinical symptoms raise suspicion of new DVT or pulmonary embolism.+
  1. 1Assess stability and bleeding contraindications and begin therapeutic LMWH while arranging objective testing when appropriate.
  2. 2

Complications

01

Fatal pulmonary embolism

Large embolic burden can overwhelm right ventricular function and produce circulatory collapse, requiring immediate resuscitation and consideration of reperfusion therapy.

02

Persistent venous or pulmonary symptoms

Post-thrombotic syndrome or chronic thromboembolic pulmonary disease may impair later function and warrant follow-up when swelling or breathlessness persists.

03

Treatment-associated bleeding

Anticoagulation can worsen obstetric or procedural bleeding, while unsafe neuraxial timing can cause spinal haematoma, making coordinated interruption and restart essential.

Monitoring and follow-up

  • Review injection adherence, bruising, bleeding and changing weight or renal function at follow-up, not just the risk-score total.
  • Keep the last-dose time visible during labour assessment and in any anaesthetic handover.
  • For standard prophylaxis, do not remove an epidural catheter within twelve hours of the last dose and wait at least four hours after spinal placement or catheter removal before LMWH, subject to the full anaesthetic plan.
  • Reassess postpartum risk if infection, prolonged admission, surgery or reduced mobility persists beyond the initial prescription period.
  • Arrange review after acute VTE for treatment duration, post-thrombotic symptoms, persistent dyspnoea and future contraception or pregnancy advice.

Special situations

Prophylaxis is not exclusion

A patient receiving prophylactic LMWH can still develop VTE, so new symptoms need the same careful diagnostic response.

DVT can be proximal

Pelvic thrombosis may produce whole-leg swelling with buttock or back pain and can be missed if investigation focuses only on a tender calf.

Duration has two conditions

An acute event needs both a minimum total treatment course and a minimum postpartum course; satisfying only one can stop anticoagulation too early.

Bleeding and thrombosis coexist

Postpartum haemorrhage can temporarily prevent heparin use while also increasing subsequent VTE risk, so reassessment after haemostasis is essential.

Common pitfalls

  1. 01

    Repeating a booking risk score unchanged despite a later admission with infection or immobility.

  2. 02

    Prescribing a prophylactic dose for a newly diagnosed proximal DVT.

  3. 03

    Ruling out PE from normal saturation, a normal ECG or an unvalidated non-pregnant risk score.

  4. 04

    Performing an epidural without verifying dose intensity, last injection time and renal function.

  5. 05

    Stopping anticoagulation at delivery after an antenatal PE.

  6. 06

    Treating every anticoagulant as interchangeable for pregnancy, breastfeeding and mechanical-valve indications.

Why
Address a specific management question in high-risk or unusual circumstances.
Interpretation and limitations
Neither is a universal acute test; pregnancy and anticoagulation affect some thrombophilia results, so specialist timing and interpretation matter.
Use ultrasound for leg symptoms and a documented PE imaging pathway for chest symptoms, involving senior clinicians if tests are inconclusive.
  • 3EscalationEscalate shock or collapse immediately to the multidisciplinary team for resuscitation and consideration of thrombolysis or other reperfusion.
    • 03Delivery planningBalance thrombosis prevention with bleeding safetyA pregnant patient receiving heparin approaches delivery or reports labour or bleeding.+
    1. 1Advise no further injections once labour or vaginal bleeding starts and arrange maternity reassessment with the exact last-dose time.
    2. 2Coordinate planned interruption, neuraxial eligibility and catheter removal with anaesthesia, accounting for dose intensity and renal function.
    3. 3Restart only when haemostasis and anaesthetic timing permit, and document the postpartum duration and responsible follow-up service.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    Prevents VTE when the maternity risk assessment supports pharmacological prophylaxis.

    Enoxaparin standard prophylaxis

    RCOG suggested subcutaneous daily doses by weight are 20 mg below 50 kg, 40 mg at 50–90 kg, 60 mg at 91–130 kg, 80 mg at 131–170 kg and 0.6 mg/kg above 170 kg; prescribe the indicated antenatal or postpartum duration.

    These are prophylactic doses, not acute-VTE treatment or mechanical-valve therapy; adjust for renal impairment and bleeding risk and check higher-dose scheduling with the maternity protocol.

    Treats confirmed VTE or sufficiently suspected VTE while diagnostic testing proceeds.

    Enoxaparin therapeutic treatment

    A commonly used pregnancy treatment regimen is 1 mg/kg subcutaneously every twelve hours using booking or early-pregnancy weight; continue through pregnancy and at least six weeks postpartum, with at least three months total treatment.

    RCOG permits locally specified once- or twice-daily regimens because evidence does not establish one universal schedule; renal impairment, extreme weight, recurrence and peripartum timing require specialist adjustment.